1. Ciencia

Thursday, 20th November
10.30-10.45 Opening remarks
Carlos Camps, Hospital General Universitario, Valencia
Past, present and future of the Spanish Lung Cancer Group
SESSION 1
Cancer biology and lung cancer origins: improving knowledge for better treatment
10.45-10.55
Is Helicobacter Pylori a cause of lung cancer?
10.55-11.05
HPV in exhaled breath condensate of lung cancer patients
11.05-11.15
Role of the SWI/SNF and MYC/MAX pathways in lung cancer development
11.15-11.25
Complement activation pathway elements as diagnostic markers and therapeutic
targets in NSCLC
Chairpersons:
Luis Montuenga, Universidad de Navarra, Pamplona (Navarra)
Florentino Hernando Trancho, Hospital Clínico San Carlos, Madrid
Cristina Teixidó, Pangaea Biotech, Barcelona
Cristina Queralt, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Montserrat Sánchez-Céspedes, Instituto de Investigación Biomédica de Bellvitge, L’Hospitalet de
Llobregat (Barcelona)
Rubén Pío, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona (Navarra)
11.25-11.35
Moving forward to solving the problem of predicting relapse in early NSCLC patients
11.35-11.50
Keynote lecture:
How to improve the outcome of SCLC patients: a message from a basic researcher
11.50-12.00
Questions & answers. Conclusions
SESSION 2 Liquid biopsy
12.00-12.10
Circulating tumor cells in lung cancer. What is the reality? New promises in mRNA
and mutational analysis
Chairpersons: 12.10-12.20
Ernest Nadal, ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat (Barcelona)
Jun Yokota, Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona (Barcelona)
Federico Rojo, Fundación Jiménez Díaz, Madrid
TBA
Alexandra Voutsina, University of Crete, School of Medicine, Heraklion, Greece
EGFR, KRAS, BRAF, MET, PIK3CA mutations and ALK translocations in blood platelets.
A novel approach for diagnosis and monitoring
Thomas Würdinger, VU University Medical Center, Amsterdam, The Netherlands
12.20-12.30
EGFR mutations in circulating tumor DNA. The EURTAC experience
12.30-12.40
KRAS and BRAF mutations in circulating tumor DNA
TBA
Clara Mayo, Instituto Univ. USP Dexeus, Barcelona
Plenary Session
& VII Educational Symposium
of the Spanish Lung Cancer Group
12.40-12.50
The role of SNPs in NSCLC
12.50-13.00
Taking cancer cells out of circulation. Induction of patient-specific tumors in mice
and prediction of response to chemotherapy
13.00-13.10
Eloísa Jantus, Hospital General Universitario, Valencia
Alberto Villanueva, ICO, Institut d’Investigació Biomèdica de Bellvitge (Barcelona) Metabolomics by NMR facilitates the non-invasive diagnosis and staging of
NSCLC
Antonio Pineda, Centro de Investigación Príncipe Felipe, Valencia
13.10-13.20
Questions & answers. Conclusions
13.20-15.00
Lunch
SESSION 3
Die another day: Targeted therapies in KRAS driven NSCLC
KRAS mutations linked to poor prognosis and resistance to therapy
15.00-15.10
State of art KRAS mutations in lung cancer
15.10-15.20
KRAS mutations associated with folate pathway activity (tumor expression of
MTHFD2 predicts response to pemetrexed)
Chairpersons:
15.20-15.30
15.30-15.40
15.40-15.50
15.50-16.05
16.05-16.15
TBA
TBA
Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Rosario García-Campelo, Complejo Hospitalario Univ. A Coruña
Autophagy dependence in KRAS driven tumors with production of secreted factors
and Pivotal role for SMYD3 in the regulation of oncogenic Ras signaling
Niki Karachaliou, Hospital Univ. Quirón Dexeus, Barcelona
Small molecule inhibition of KRAS-PDE interaction impairing oncogenic KRAS
signaling
Roger Estrada, Universitat Ramon Llull, Barcelona
Synthetic lethal combinations in KRAS NSCLC cell lines combining gefitinib/
erlotinib with an AXL inhibitor. Compound 16
Silvia García-Román, Universitat Ramon Llull, Barcelona
Keynote lecture:
What is the usefulness of p53 mutations in large cohorts of EGFR-mutated, EGFR
TKI treated, or non-mutated chemotherapy treated lung cancer patients? Miguel Ángel Molina, Hospital Univ. Quirón Dexeus, Barcelona
Questions & answers. Conclusions
Plenary Session
& VII Educational Symposium
of the Spanish Lung Cancer Group
SESSION 4 The renaissance of customizing chemotherapy and targeted therapy
16.15-16.25
New clues in ERCC1 prompting the PIPSeN study – olaparib maintenance in
platinum-sensitive NSCLC
Chairpersons:
Juan Coves, Hospital Son Llàtzer, Palma de Mallorca
Manuel Cobo, Hospital Univ. Carlos Haya, Málaga
Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France
16.25-16.35
The predictive role of BRCA1/53BP1 and HERC2 mRNA in advanced NSCLC patients
16.35-16.45
The emerging role of bridging molecules in BRCA complexes. Key role of PALB2 in the BREC
16.45-16.55
Results of BRCA pathway analysis in the NATCH study
16.55-17.05
The burning need to repurpose drugs in NSCLC and SCLC
17.05-17.20
Keynote lecture:
Biomarkers for exploiting the vulnerabilities of DNA repair deficiency or proficiency
17.20-17.30
Questions & answers. Conclusions
17.30-18.00 Coffee Break
SESSION 5
Second and third generation EGFR TKIs
18.00-18.10
State of the art in second generation EGFR TKIs: afatinib & dacomitinib
18.10-18.20
State of the art in third generation EGFR TKIs: AZ9291, CO-1686, HM61713
18.20-18.30
Lessons from the BELIEF
18.30-18.40
Synthetic lethal therapy with EGFR TKIs plus repurposing drugs in EGFR mutant lung
cancer customized by BIM mRNA expression
Chairpersons:
18.40-18.55
18.55
Laura Bonanno, Istituto Oncologico Veneto, Padova, Italy
Niki Karachaliou, Hospital Univ. Quirón Dexeus, Barcelona
Imane Chaib, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Mariacarmela Santarpia, Istituto Europeo di Oncologia, Messina, Italy
Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo (Asturias)
Manuel Dómine, Fundación Jiménez Díaz, Madrid
Teresa Morán, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Pilar Lianes, Hospital de Mataró, Mataró (Barcelona)
Santiago Ponce, Hospital Univ. 12 de Octubre, Madrid
Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Keynote lecture:
Characterization of irreversible EGFR mutant selective EGFR inhibitors. What we
need to know.
Roger Estrada, Universitat Ramon Llull, Barcelona
Questions & answers. Conclusions
Friday, 21st November
08.00-09.00
SLCG Plenary Session
SESSION 6
Recent result in advanced NSCLC
09.00-09.15
Keynote lecture:
Immune based anti-tumor therapies. PD1 & PDL1 blockade
09.15-09.30
Keynote lecture:
Antiantiogenic strategies
09.30-09.45
Keynote lecture:
ALK Target Therapies
09.45-09.55
Questions & answers. Conclusions
SESSION 7
Diagnostic clinical genome and exome sequencing
09.55-10.05
Sequencing of the genome or exome for clinical applications
10.05-10.15
Actionable diagnosis of lung cancer by next generation sequencing
10.15-10.25
Treatment of ROS1 lung cancer patients: the EUCROSS trial
10.25-10.35
Opportunities to treat other driver alterations such as RET and NTRK
10.35-10.45
Treatment of BRAF mutant NSCLC patients
10.45-11.00
Keynote lecture:
Current practice in diagnostic clinical genome
11.00-11.10
Questions & answers. Conclusions
11.10-11.30
Coffee break
Chairpersons:
Chairpersons:
Jürgen Wolf, Center for Integrated Oncology, University of Cologne, Germany
Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Enriqueta Felip, Hospital General Vall d’Hebron, Barcelona Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona
Amelia Insa, Hospital Clínico Universitario, Valencia
Angel Artal, Hospital Univ. Miguel Servet, Zaragoza
Natividad Martínez, Hospital General Universitario, Elche (Alicante)
Trever Bivona, University of California, San Francisco (California), USA
Julie George, Center for Integrated Oncology, University of Cologne, Germany
Jürgen Wolf, Center for Integrated Oncology, University of Cologne, Germany
Ignatius Ou, University of California Irvine Medical Center, Orange (California), USA
José Miguel Sánchez, Hospital Univ. de La Princesa, Madrid
Fernando López-Ríos, Centro de Investigaciones Oncológicas Clara Campal, Madrid
Plenary Session
& VII Educational Symposium
of the Spanish Lung Cancer Group
SESSION 8
Moving forward to improving curability in locally advanced NSCLC. What’s new?
11.30-11.40
Salvage surgery following chemoradiotherapy
11.40-11.50
How can we reconcile chemoradiotherapy with or without surgery for locally
advanced NSCLC?
Chairpersons:
Felipe Cardenal, ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat (Barcelona)
Manuel de las Heras, Hospital Clínico San Carlos, Madrid
Laura Romero, Hospital Univ. Vall d’Hebron, Barcelona
TBA
11.50-12.00
New opportunities to treat: RENO trial
12.00-12.10
Novel expectations in chemoradiotherapy
12.10-12.20
Questions & answers. Conclusions
SESSION 9
Novel perspectives in management of early stage NSCLC
12.20-12.30
SCAT results of customized adjuvant chemotherapy in state II and III resected
NSCLC patients
Chairpersons: Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza
Wilfried Eberhardt, West German Cancer Center, Essen, Germany
Marcelo Jiménez, Hospital Universitario de Salamanca
José Luis González Larriba, Hospital Clínico San Carlos, Madrid
Bartomeu Massutí, Hospital General Universitario, Alicante
12.30-12.45
Management of stage I NSCLC patients
12.45-13.00
Keynote lecture:
What we can expect in the next two years. The hope for SCLC and increased
survival in NSCLC patients
Javier de Castro, Hospital Univ. La Paz, Madrid
Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)
13.00-13.15
Keynote lecture:
State of the art in mesothelioma
13.15-13.25
Questions & answers. Conclusions
13.25-13.45
Closing Remarks
Noemí Reguart, Hospital Clínic Universitari, Barcelona
Scientific Committee
Carlos Camps, Hospital General Universitario, Valencia
Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Felipe Cardenal, ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat (Barcelona)
Manuel Cobo, Hospital Univ. Carlos Haya, Málaga
Juan Coves, Hospital Son Llàtzer, Palma de Mallorca
Javier de Castro, Hospital Univ. La Paz, Madrid
Manuel Dómine, Fundación Jiménez Díaz, Madrid
Rosario García Campelo, Complejo Hospitalario Universitario, A Coruña
José Luis González Larriba, Hospital Clínico Univ. San Carlos, Madrid
Florentino Hernando-Trancho, Hospital Clínico Univ. San Carlos, Madrid
Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza
Eloísa Jantús, Hospital General Universitario, Valencia
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona
Bartomeu Massutí, Hospital General Universitario, Alicante
Teresa Morán, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid)
Noemí Reguart, Hospital Clínic Universitari, Barcelona
Delvys Rodríguez, Hospital Univ. Insular de Gran Canaria, Las Palmas
Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona)
José Javier Sánchez, Universidad Autónoma de Madrid
José Miguel Sánchez, Hospital Univ. de la Princesa, Madrid
Miquel Taron, Pangaea Biotech, Barcelona
Venue
Hotel NH Eurobuilding
Sala Madrid
c/ Padre Damián, 23
28036 Madrid
Holding a badge will be required to access the meeting room
Language
Lectures will be delivered in English or Spanish.
Credits
Accreditation requested to the “Consell Català de Formació Continuada de les
Professions Sanitàries”
Supporting Companies
Symposium Secretariat
Monasterios de Suso y Yuso 34, 4-14-2 · 28049 Madrid
Tel.: +34 91 372 02 03 · E-mail: [email protected]
www.doctaforum.com/gecp